Efficacy of 23-valent pneumococcal vaccine in the outcome of pneumococcal bacteremia and hospitalization due to community acquired pneumonia in patients aged 60 years and older, seen at FEU-NRMF Medical Center emergency department from January 1, 2010 to January 1, 2011 : a retrospective cohort study /
Marivi V. Allaga and Pio Esguerra.
- Fairview, Quezon City: Department of Internal Medicine, FEU-NRMF, 2011.
- 20 pages: (in folder)
Includes appendices and bibliographical references.
Abstract: Streptococcus pneumonia is the cause of Pneumonia in older adults, but it remains whether the use of the Pneumococcal Polysaccharide Vaccine alters the overall risk of Community Acquired Pneumonia. In this retrospective cohort study 150 adults aged 60 years and older diagnosed with Community Acquired Pneumonia were assessed. The primary outcomes were (1) hospitalization due to Community Acquired Pneumonia (2) patients who are treated on an outpatient basis and (3) those who developed Pneumococcal bacteremia. The results showed no significant association between Pneumococcal vaccination status and hospitalization due to Community Acquired Pneumonia as proven by the p value of 0.51. Patients who were not vaccinated had higher risk of bacteremia (RR=1.81; 95% Cl = 0.93 - 5.19) hence it is cost effective to use the vaccine in older adults for the prevention of invasive Pneumococcal disease. These findings support that there is a reduced risk of Pneumococcal bacteremia, the outcome most directly linked to pneumococcal infection, among vaccinated persons who developed Community Acquired Pneumonia and no relation between the risk of hospitalization due to Community Acquired Pneumonia and the time since vaccination.